Urogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Buy" by Brokerages

Shares of Urogen Pharma (NASDAQ:URGN - Get Free Report) have received an average rating of "Buy" from the eight brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $32.86.

URGN has been the topic of a number of analyst reports. Guggenheim reissued a "buy" rating and set a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the company a "neutral" rating in a report on Friday, June 13th. HC Wainwright raised Urogen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price objective on the stock in a report on Monday, June 16th. D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of Urogen Pharma in a report on Thursday, June 12th. Finally, Oppenheimer set a $31.00 price objective on Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th.

Urogen Pharma Stock Down 2.4%

URGN opened at $14.30 on Tuesday. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $18.15. The business has a 50-day moving average of $9.06 and a 200-day moving average of $10.11. The company has a debt-to-equity ratio of 4.77, a current ratio of 5.65 and a quick ratio of 5.47. The company has a market capitalization of $659.37 million, a PE ratio of -4.50 and a beta of 0.40.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. The firm had revenue of $20.25 million for the quarter, compared to analysts' expectations of $22.71 million. Equities research analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the sale, the insider now owns 153,378 shares of the company's stock, valued at $1,130,395.86. This trade represents a 3.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 5.10% of the company's stock.

Institutional Trading of Urogen Pharma

Several institutional investors have recently modified their holdings of URGN. Rhumbline Advisers grew its holdings in shares of Urogen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock worth $546,000 after purchasing an additional 1,402 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Urogen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock worth $1,001,000 after buying an additional 6,430 shares during the period. ARK Investment Management LLC lifted its position in shares of Urogen Pharma by 15.2% during the 4th quarter. ARK Investment Management LLC now owns 140,148 shares of the company's stock worth $1,493,000 after buying an additional 18,514 shares during the period. Oppenheimer & Co. Inc. bought a new position in shares of Urogen Pharma during the 4th quarter worth approximately $126,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Urogen Pharma by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock worth $996,000 after buying an additional 3,024 shares during the period. Institutional investors and hedge funds own 91.29% of the company's stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.